Audit of the use of erythromycin in the treatment of community-acquired lower respiratory infections

Jolley, Alan; Davies, A.C.; McLeod, D T

doi:10.1016/s0954-6111(96)80011-4

Cited by 7 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antibiotics chosen for inclusion in the study were classified into two groups; those with a narrow range of therapeutic indications (rifampicin and isoniazid) and those with a broad-spectrum of antimicrobial activity (clarithromycin and erythromycin). It is recognised that the broad-spectrum agents have a greater variation in use and are often over-prescribed and used unnecessarily [11]. Therefore, it was expected that there would be a wide variation in DDD/FCE ratios between individual trusts for these two antibiotics.…”

Section: Partmentioning

confidence: 99%

Evaluation of a tool to benchmark hospital antibiotic prescribing in the United Kingdom

Fitzpatrick

Edwards

2007

Pharm World Sci

View full text Add to dashboard Cite

show abstract

Section: Partmentioning

confidence: 99%

Evaluation of a tool to benchmark hospital antibiotic prescribing in the United Kingdom

Fitzpatrick

Edwards

2007

Pharm World Sci

View full text Add to dashboard Cite

show abstract

“…Audits of practice guidelines and care pathways for patients hospitalized with CAP have shown that, while compliance can be a problem [144,164,165], these strategies can improve the quality of health-care and reduce health-care resource consumption [162,166,167]. Fewer data are available in the outpatient setting.…”

Section: A U D I T I N G G U I D E L I N E Smentioning

confidence: 99%

A critical assessment of published guidelines and other decision‐support systems for the antibiotic treatment of community‐acquired respiratory tract infections

Finch¹,

Low²

2002

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Guidelines are an important means by which professional associations and governments have sought to improve the quality and cost-effectiveness of disease management for infectious diseases. Prescribing of initial antibiotic therapy for community-acquired respiratory tract infections (RTIs) is primarily empiric and physicians may often have a limited appreciation of bacterial resistance. Recent guidelines for managing RTIs have adopted a more evidence-based approach. This process has highlighted important gaps in the existing knowledge base, e.g. concerning the impact of resistance on the effectiveness of oral antibiotics for outpatient community-acquired pneumonia and the level of resistance that should prompt a change in empiric prescribing. In upper RTIs, the challenge is to identify patients in whom antibiotic therapy is warranted. Concentrated, sustained efforts are needed to secure physicians' use of guidelines. The information should be distilled into a simple format available at the point of prescribing and supported by other behavioral change techniques (e.g. educational outreach visits). Advances in information technology offer the promise of more dynamic, computer-assisted forms of guidance. Thus, RTI prescribing guidelines and other prescribing support systems should help control bacterial resistance in the community. However, their effect on resistance patterns is largely unknown and there is an urgent need for collaborative research in this area. Rapid, cost-effective diagnostic techniques are also required and new antibiotics will continue to have a role in disease management.

show abstract

Pneumonia

Seaton¹

2000

Crofton and Douglas's Respiratory Diseases

View full text Add to dashboard Cite

Audit of the use of erythromycin in the treatment of community-acquired lower respiratory infections

Cited by 7 publications

References 4 publications

Evaluation of a tool to benchmark hospital antibiotic prescribing in the United Kingdom

Evaluation of a tool to benchmark hospital antibiotic prescribing in the United Kingdom

A critical assessment of published guidelines and other decision‐support systems for the antibiotic treatment of community‐acquired respiratory tract infections

Pneumonia

Contact Info

Product

Resources

About